Work

A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Year: 2019

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2019-124050

Authors: Mikkael A. Sekeres, Michael W. Schuster, Magalie Joris, Jürgen Krauter, Johan A. Maertens, Emmanuel Gyan, Tibor Kovacsovics, Amit Verma, Paresh Vyas, Eunice S. Wang, Weidong Wendy Ma, Mirjana Zeremski, Arthur Kudla, Geoffrey Chan, Amer M. Zeidan

Institutions: Cleveland Clinic, Stony Brook University Hospital, Centre Hospitalier Universitaire Amiens-Picardie, Klinikum Braunschweig, Universitair Ziekenhuis Leuven, Centre Hospitalier Universitaire de Tours, Huntsman Cancer Institute, Albert Einstein College of Medicine, Montefiore Medical Center, Montefiore Einstein Comprehensive Cancer Center, University of Oxford, MRC Weatherall Institute of Molecular Medicine, MRC Molecular Haematology Unit, Roswell Park Comprehensive Cancer Center, Pfizer (United States), Yale Cancer Center, Yale University

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2989737435

Cites:

Cited by: 16

Related to: 10